Other Agreements - Additional Information (Details)	12 Months Ended
	Dec. 31, 2019 USD ($) shares	Dec. 31, 2018 USD ($)
Other Agreements [Line Items]
Upfront consideration paid in exchange of common stock | shares	5,587
Asset purchase agreement fixed payments paid for first two years	$ 740,000
Asset purchase agreement aggregate cash compensation paid	15,000,000
Accretion expense	(13,821)	$ (12,480)
Research and development	$ 10,570,225	12,598,034
Agreement expiration date	May 31, 2027
Description on termination of agreement	The Company may terminate the Restated Agreement at any time upon 90 days’ written notice and may terminate any development plan under the Restated Agreement upon 30 days’ prior written notice. Illumina may terminate the Restated Agreement upon 30 days’ prior written notice if the Company undergoes certain changes of control, subject to a transition period of up to 12 months for then-ongoing development plans. Either party may terminate the Restated Agreement upon the other party’s material breach of the Restated Agreement that remains uncured for 30 days, or upon the other party’s bankruptcy.
Illumina, Inc. Agreement
Other Agreements [Line Items]
Aggregate payment upon achievement of specified regulatory milestones	$ 600,000
Research and development	$ 0	12,500
Agreement termination notice period	90 days
Development plan agreement termination notice period	30 days
Number of days material breach remains uncured	30 days
Measurement Input, Default Rate [Member]
Other Agreements [Line Items]
Discount rate used to calculate asset purchase obligation	2.5
NuvoGen Asset Purchase Agreement
Other Agreements [Line Items]
Percentage on annual revenues for cash consideration to be paid	6.00%
Asset purchase agreement yearly fixed fees paid	$ 400,000	400,000
Accrued revenue-based payments	927,922	612,122
Additional revenue based payments payable	$ 187,997	363,686
Percentage of compounded annual interest on unpaid Obligation	2.50%
NuvoGen
Other Agreements [Line Items]
Convertible notes and related debt discount	$ (92,311)	(106,132)
Accretion expense	$ (13,821)	$ (12,480)